Results 91 to 100 of about 2,463,575 (352)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Data Snapshot: Faces of Falls

open access: yesPatient Safety, 2019
Falls are a common and often devastating health threat for hospitalized patients, as they can cause serious injuries such as a hip fracture, and even lead to death.1 Falls in Pennsylvania continue to be one of the biggest contributors to patient harm and
Susan C. Wallace, Caitlyn Allen
doaj   +1 more source

Advancing Patient Safety in the U.S. Department of Veterans Affairs [PDF]

open access: yes, 2011
As part of a systemwide transformation, the VA formed its National Center for Patient Safety to foster an organizational culture of safety within its nationwide network of hospitals and outpatient clinics.
Deborah Chase, Douglas McCarthy
core  

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study

open access: hybrid, 2021
Nuria Carrillo   +21 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Batteries Gone Bad

open access: yesPatient Safety, 2019
A battery's moment of death may come as a beep, a red warning light, or a complete surprise. If you are lucky (i.e., prepared), you have a power cord or backup battery handy.
Kim Liberatore, Barry Kohler
doaj   +1 more source

Adverse events in veterans affairs inpatient psychiatric units: Staff perspectives on contributing and protective factors. [PDF]

open access: yes, 2017
OBJECTIVES: This study sought to identify risk factors and protective factors in hospital-based mental health settings in the Veterans Health Administration (VHA), with the goal of informing interventions to improve care of persons with serious mental ...
Cullen, Sara W.   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy